Nordic Nanovector ASA announced that following the decisions to discontinue the PARADIGME study for its lead asset Betalutin®, restructure the company and appoint Carnegie Investment Bank to explore strategic options three members of the Company's Board have decided to step down. Solveig Hellebust, Jean Pierre Bizzari and Thomas Ramdahl will step down from the Board with immediate effect. The decision by these Board members to relinquish their Board positions following the downsizing of the Company will support the preservation of financial resources during this strategic process while retaining the necessary personnel needed to maximise the chances of a successful conclusion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.03 NOK | 0.00% | 0.00% | -20.16% |
Feb. 28 | Transcript : Thor Medical ASA, H2 2023 Earnings Call, Feb 28, 2024 | |
Feb. 14 | Thor Medical ASA Announces CEO Changes | CI |
1st Jan change | Capi. | |
---|---|---|
-20.16% | 22.64M | |
+8.19% | 115B | |
+13.09% | 107B | |
-13.42% | 22.31B | |
-3.99% | 21.6B | |
-5.62% | 18.23B | |
-39.93% | 17.62B | |
+7.73% | 14.26B | |
+33.69% | 12.37B | |
-28.32% | 8.28B |
- Stock Market
- Equities
- NANOV Stock
- News Thor Medical
- Nordic Nanovector ASA Announces Board Changes